FIELD: medicine.
SUBSTANCE: invention relates to a PDE1 inhibitor applicable in medicine, characterized by a structure selected from:
, 
, 
, 
, 
, a pharmaceutical composition based thereon for treating and preventing the disease, CNS disorders or injuries.
EFFECT: novel effective PDE1 inhibitors with prolonged half-life in vivo are proposed for treating diseases, disorders and injures of the brain and spinal cord.
11 cl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORGANIC COMPOUNDS | 2014 |
|
RU2679142C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2709786C2 |
| METHODS OF TREATING CANCER DISEASES AND TUMORS USING PDE1 INHIBITORS | 2019 |
|
RU2811918C2 |
| TETRAHYDRO-PYRAZOLO[1,5-a]PYRIDO-PYRIMIDINES - SEROTONIN 5-HT RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2008 |
|
RU2391343C1 |
| METHODS OF TREATMENT | 2020 |
|
RU2822394C1 |
| SUBSTITUTED 2-AMINO-3-SULFONYL-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIDO-PYRIMIDINES-ANTAGONISTS OF SEROTONIN 5-HT RECEPTORS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2008 |
|
RU2384581C2 |
| SALT CRYSTALS | 2013 |
|
RU2652116C2 |
| SUBSTITUTED 2-ALKYLSULFANYL-3-SULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES, SEROTONIN 5-HT RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2008 |
|
RU2393159C1 |
| COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | 2013 |
|
RU2657540C2 |
| SUBSTITUTED CYCLOALKANO[e OR d]PYRAZOLO[1,5-a]PYRIMIDINE-ANTAGONISTS OF SEROTONIN 5-HT RECEPTORS, METHOD OF PRODUCING SAID COMPOUNDS AND USE | 2008 |
|
RU2374249C1 |
